Literature DB >> 400818

Pneumocystis carinii infection: evidence for high prevalence in normal and immunosuppressed children.

L L Pifer, W T Hughes, S Stagno, D Woods.   

Abstract

Using Pneumocystis carinii organisms propagated through three passages in embryonic chick epithelial lung cultures, specific antigens and antisera were prepared for use in counterimmunoelectrophoresis and indirect immunofluorescent antibody techniques. These methods proved to be specific and sensitive for the detection of P. carinii antigen and antibody, respectively, in sera, and were applied to the study of cancer patients with P. carinii pneumonitis (PCP), cancer patients without pneumonitis, and normal children. Antigenemia was detected in 95% of patients with PCP, in 15% of cancer patients without pneumonitis, and in none of the normal children tested. In cross-sectional and longitudinal studies of normal infants and children, acquisition of serum antibody to P. carinii was demonstrated to occur progressively with increase in age. By 4 years of age two thirds of the normal children were found to have antibody to P. carinii in titers of 1:16 or greater. These studies indicate that subclinical P. carinii infection is highly prevalent in normal children, analogous to other opportunistic infections where active disease is manifest predominantly in the compromised host.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 400818

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  113 in total

1.  Magnetic bead capture eliminates PCR inhibitors in samples collected from the airborne environment, permitting detection of Pneumocystis carinii DNA.

Authors:  N Maher; H K Dillon; S H Vermund; T R Unnasch
Journal:  Appl Environ Microbiol       Date:  2001-01       Impact factor: 4.792

Review 2.  Immunological features of Pneumocystis carinii infection in humans.

Authors:  P D Walzer
Journal:  Clin Diagn Lab Immunol       Date:  1999-03

3.  Seroepidemiological study of Pneumocystis jirovecii infection in healthy infants in Chile using recombinant fragments of the P. jirovecii major surface glycoprotein.

Authors:  Kpandja Djawe; Kieran R Daly; Sergio L Vargas; M Elena Santolaya; Carolina A Ponce; Rebeca Bustamante; Judith Koch; Linda Levin; Peter D Walzer
Journal:  Int J Infect Dis       Date:  2010-12       Impact factor: 3.623

Review 4.  Extrapulmonary pneumocystosis.

Authors:  V L Ng; D M Yajko; W K Hadley
Journal:  Clin Microbiol Rev       Date:  1997-07       Impact factor: 26.132

5.  Does cyclosporin A adversely affect Pneumocystis carinii infection?

Authors:  R J McGonigle; M Beaman; J Stone; J Young; J Michael; D Adu
Journal:  Postgrad Med J       Date:  1988-09       Impact factor: 2.401

6.  Pneumocystis carinii antigenemia in acquired immunodeficiency syndrome.

Authors:  L W Pifer; B L Wolf; J J Weems; D R Woods; C C Edwards; R E Joyner
Journal:  J Clin Microbiol       Date:  1988-07       Impact factor: 5.948

7.  Pneumocystis carinii antigen detection in rat serum and lung lavage.

Authors:  S J McNabb; D C Graves; S D Kosanke; M J Moyer; M H Ivey
Journal:  J Clin Microbiol       Date:  1988-09       Impact factor: 5.948

8.  Pneumocystis jerovecii pneumonia in a patient with untreated chronic lymphocytic leukaemia: a novel case and postulations concerning the mechanism.

Authors:  Alexandros Kalkanis; Marc A Judson; Mark B Napier
Journal:  BMJ Case Rep       Date:  2013-11-28

Review 9.  Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients.

Authors:  Martin Rodriguez; Jay A Fishman
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

10.  Nucleotide sequence variation in Pneumocystis carinii strains that infect humans.

Authors:  C H Lee; J J Lu; M S Bartlett; M M Durkin; T H Liu; J Wang; B Jiang; J W Smith
Journal:  J Clin Microbiol       Date:  1993-03       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.